We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
- Authors
Fonsatti, Ester; Di Giacomo, Anna Maria; Maio, Michele
- Abstract
Passive immunotherapy with monoclonal antibodies (mAb) targeted to specific tumor-associated antigens is amongst the most rapidly expanding approaches to biological therapy of cancer. However, until now a limited number of therapeutic mAb has demonstrated clinical efficacy in selected neoplasia. Results emerging from basic research point to a deeper characterization of specific biological features of neoplastic cells as crucial to optimize the clinical potential of therapeutic mAb, and to identify cancer patients who represent the best candidates to antibodybased immunotherapy. Focus on the tissue distribution and on the functional role of membrane complement-regulatory proteins such as Protectin (CD59), which under physiologic conditions protects tissues from Complement (C)-damage, might help to optimize the efficacy of immunotherapeutic strategies based on C-activating mAb.
- Subjects
IMMUNOTHERAPY; CLINICAL immunology; MONOCLONAL antibodies; TUMOR antigens; CLINICAL trials; CANCER
- Publication
Journal of Translational Medicine, 2004, Vol 2, p1
- ISSN
1479-5876
- Publication type
Article